Member Info for Troutisout1

Have been juggling this predicament with this and another big rising share and the long and the short of it is that you need to load up the ISA before the share takes off. With the CGT allowance now at £3k it really doesn't cushion you.

Transfers to Spouse do not create a CGT moment, however to anyone else they do.

You can transfer into a pension, but although the limit is £60k, I believe you cannot transfer more than you are going to earn in that year.

The other thing is to always register any CGT losses if they arise to HMRC, I sold out of these several years back and registered a large CGT loss, which will be used against some of the gains now, but only because I registered the loss carried forward each year in my tax return.

Obviously not at any price?

Your obsession with placees continues, it doesn't matter, there were 2 billions shares already in issue and many of them are also very much in profit.

We get sellers, we have buyers, it really doesn't matter when or how they bought their shares...

Ontarget, the buy print was first and then the sell, there would be no point in doing it just to make a loss.

No sell showing though?

Well looks like 300k of buys there, any more as they were before the tick back up?

Laura, wondered when the third part of the triangle would turn up...

You even pretended to invest in FAB to post on the board, the difference is that FAB do not post any contracts that aren't deemed material, so the minnow contracts that PYC RNS wouldn't happen there. The reason that FAB has a higher valuation is it has several platforms one of which has been 'validated' and it took 2 years (DoseMeRx has being trialling with clinicians for how many 5/6months). It was validated by the NCI in US and they liked it so much they want to continue to use it, a license agreement has been discussed but due to the nature and size of the deal, the final decision has to be taken by the NIH in the US and that will take time.

KH mentioned earlier that PYC has a unique offering, I would suggest it has some unique parts but the majority of it's business PK/PD simulation and Biometrics are being done by most CROs now and most are big enough to offer more than just that, they will be offering trial recruitment, Lab services, QA and facilities to conduct trials, HVO for one has just bought and integrated a German CRO, offering all of these things and have added that to their Venn offering and their HLabs and HCTs to make an integrated offering. They also sit on a cash pile so have no problems with DD from larger clients.

That's the problem here, not me or any other poster, the fact is they don't have enough money and we know what that means, they will have to raise it somehow...

Oh look one is still here...LOL!

Even he must be thinking this is hard work to pump, it would seem most of his twitter followers have bailed on him.

Just joined you for lunch and can have a dessert with mine (2 x 500k). I love doing this, it seems crazy but sometimes happens that they are bidding more than they are offering at...Our trades are delayed reporting though.

Another sub 14p dip gets picked off, was there a big sell? Only lots of stock available to buy just then

We've gone through that before and what has actually happened since that RNS??? Nothing as it will take money for PYC to do any of their side of the areas of collaboration. Cash it doesn't have!

You can polish it as much as you want but without a far greater financial foundation this is all talk, they are unlikely to get through to any sort of breakeven point without more substantial funds and they aren't going to be signing any licenses until the product is fully developed which according to the Interims isn't any time soon.

Now this post is epic in it's manipulation of the facts!

The Company state that the Beyond Blood trial won't actually finish recruiting until March this year due to delays (again!) and will take several more months to get results coming in, so they have entered into a Data usage Agreement, this isn't a validation of anything the Company is doing, they need more data to progress their product and have had to go and pay for it from ma US University that has datasets from cancer patients undergoing treatment.

"the Company entered into a Data Usage Agreement with a leading American university, securing access to a substantial dataset from cancer patients undergoing treatment."

They need as much data as possible to develop their personalised dosing software, which is still only being used for research purposes by certain clinicians, they will then use that to refine and calibrate the dosing tool. This is still a long way from commercial launch and any fee income. It's all in black and white in the Interims RNS.

You say losses are 'shrinking' and yet the loss clearly got bigger year on year!

You say the dosing software is now 'live' on the DoseMeRx platform, yet it isn't live in the sense of available to all and we still don't know how many clinicians it may have gone out to for testing and how this has gone.

Is there a danger that you are not actually being honest here???

Cheapshareboy,

Thank's for that, I did say some brokers and did read the 'transfer of shares' (however had missed on first read the 'Outside a trading venue'. I did the same years ago to transfer to my Spouse, but that was back in the times of share certs.

Recently I tried to transfer some shares from my investment account to my Sons' ISA accounts (same broker) they were not able to transfer from accounts that weren't held in the same name or address.

When?

Why would he be in a closed period? No results due for months and the placing has been and gone, the timings of deals being signed are out of his control and we as a market have been told that discussions are ongoing with some clients.

As for the transfer to his Daughters that makes sense, I have done just the same to my Sons how ever, the transfer process with some brokers can take days, unlike a Bed and ISA they cannot just transfer the holding from one account to the other with a small cut, they have to sell and buy back once cleared.

So on that were the 2 x 100k the sells?

Someone mentioned the other Directors buying shares, one just did in the placing and two others took shares in lieu of their bonus, so they have all been adding to their holdings recently.

Looks to me like someone is playing silly b*ggers selling 3k lots all morning.

It bounced back up quick enough to suggest there is a delayed buy or two in the system.

The thing is TRENCH, it's not high enough to see them through to profitability...

Strangely the 4 delayed trades look to be sells and that is what moved the offer down from 0.65p to 0.55p.

But you will always claim black is white and white is black if it suits.

TRENCH, These were the figures from last year, yet they still needed a fundraise.

"Cash and cash equivalents of £269k at 31 December 2024

· Shareholders' funds of £418k at 31 December 2024